REBIF® OFFERS 3 DIFFERENT INJECTION OPTIONS1-3

prefilled syringe PREASSEMBLED, PREFILLED SYRINGES;

 

PREASSEMBLED, PREFILLED SYRINGES1*

  • Ready to use
  • 29-gauge needle, 1/2-inch length
  • No mixing or assembly required
Image showing prefilled syringes REBIJECT II® AUTOINJECTOR

 

REBIJECT II® AUTOINJECTOR2*

  • Works with the Rebif® prefilled syringe
  • Ability to adjust the injection depth into skin
  • Available at no additional cost
Image showing prefilled syringe  EBIF® REBIDOSE® (INTERFERON BETA-1A)

 

REBIF® REBIDOSE® (INTERFERON BETA-1A)3*

  • Preassembled, prefilled, single-use autoinjector
  • Portable, goes where you go
  • Needle remains hidden before and after injecting

 

*Images shown are not actual size.

 

Graphic of a computer screen and a mobile phone

Visit Rebif.com

To view the administration information and video instructions available for your patients

Graphic of a computer screen and a mobile phone

Visit Rebif.com

To view the administration information and video instructions available for your patients

THE ONLY INTERFERON FOR RMS WITH 2 DOSAGE STRENGTHS1†

 

Graphic showing 2 circles; on the left text saying - 22 mcg Maintain at 22 mcg or titrate up to 44 mcg' on the right text saying - 44 mcg Lower dose to 22 mcg

 

Rebif® allows you to adjust the dose to meet individual patient needs without changing therapy.1

Titration recommendations1

 

  • Generally, patients should be started at 20% of the prescribed dose 3 times per week and increased over a 4-week period to the targeted dose, either 22 mcg 3 times per week or 44 mcg 3 times per week
  • Titration may decrease the rate of flu-like symptoms
  • Patients who experience decreased peripheral blood counts or elevated liver function tests may require dose reduction or discontinuation
    • Dose may be gradually re-escalated when issue is resolved
    • If issue does not resolve, discontinue therapy

 

PRISMS was not designed to determine differences in efficacy between the 22 mcg and 44 mcg-dose groups. Both doses were shown to be effective vs placebo in the treatment of patients with relapsing forms of MS. The type of adverse events reported for 22 mcg was the same as for 44 mcg and includes, most commonly, flu-like symptoms and injection-site reactions. The incidence of leukopenia and elevated liver function tests observed was lower in patients receiving 22 mcg 3 times weekly.4

 

†Injections should be taken 3 times weekly and at least 48 hours apart.
‡Mean number of relapses at 2 years was 1.73 and 1.82 for Rebif® 44 mcg and 22 mcg, respectively, vs 2.56 with placebo.

Rebif® should be stored in the refrigerator between 36°F and 46°F (2°C and 8°C). DO NOT FREEZE. If a refrigerator is not available, Rebif® may be stored between 36°F and 77°F (2°C and 25°C) for up to 30 days and away from heat and light.

 


IMPORTANT SAFETY INFORMATION AND INDICATION

Important Safety Information

Rebif is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation.

Rebif should be used with caution in patients with depression, a condition that is common in people with multiple sclerosis. Depression, suicidal ideation, and suicide attempts have been reported to occur with increased frequency in patients receiving interferon compounds, including Rebif.

Severe liver injury, including some cases of hepatic failure requiring liver transplantation, has been reported rarely in patients taking Rebif. The potential for liver injury should be considered when used in combination with other products associated with liver injury. Monitor liver function tests and patients for signs and symptoms of hepatic injury. Consider discontinuing Rebif if hepatic injury occurs.

Anaphylaxis and other allergic reactions (some severe) have been reported as a rare complication of Rebif. Discontinue Rebif if anaphylaxis occurs.

In controlled clinical trials, injection site reactions occurred more frequently in Rebif-treated patients than in placebo-treated and Avonex-treated patients. Injection site reactions including injection site pain, erythema, edema, cellulitis, abscess, and necrosis have been reported in the postmarketing setting. Do not administer Rebif into affected area until fully healed; if multiple lesions occur, discontinue Rebif until skin lesions are healed.

Decreased peripheral blood counts in all cell lines, including pancytopenia, have been reported in Rebif-treated patients. In controlled clinical trials, leukopenia occurred at a higher frequency in Rebif-treated patients than in placebo and Avonex-treated patients. Thrombocytopenia and anemia occurred more frequently in 44 mcg Rebif-treated patients than in placebo-treated patients. Patients should be monitored for symptoms or signs of decreased blood counts. Monitoring of complete blood and differential white blood cell counts is also recommended.

Cases of thrombotic microangiopathy (TMA), some fatal, have been reported with interferon beta products, including Rebif, up to several weeks or years after starting therapy. Discontinue Rebif if clinical symptoms and laboratory findings consistent with TMA occur, and manage as clinically indicated.

Caution should be exercised when administering Rebif to patients with pre-existing seizure disorders. Seizures have been temporally associated with the use of beta interferons, including Rebif, in clinical trials and in postmarketing reports.

The most common side effects with Rebif are injection-site disorders, headaches, influenza-like symptoms, abdominal pain, depression, elevated liver enzymes, and hematologic abnormalities.

Epidemiological data do not suggest a clear relationship between interferon beta use and major congenital malformations, but interferon beta may cause fetal harm based on animal studies. Data from a large human population-based cohort study, as well as other published studies over several decades, have not identified a drug-associated risk of major birth defects with interferon beta products during early pregnancy. Findings regarding a potential risk for low birth weight or miscarriage with the use of interferon beta products in pregnancy have been inconsistent.

Indication

Rebif is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Please see Rebif® Prescribing Information  and Medication Guide.

References: 1. Rebif® [Prescribing Information]. Rockland, MA: EMD Serono, Inc. 2. Rebiject II [Instructions for Use]. Rockland, MA: EMD Serono, Inc. 3. Rebif® Rebidose® [Instructions for Use]. Rockland, MA: EMD Serono, Inc. 4. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498-1504.